Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 12 January 2018

Indication(s)

- ISENTRESS 400 mg film-coated tablets
- ISENTRESS 25 mg chewable tablets
- ISENTRESS 100 mg chewable tablets
- ISENTRESS 100 mg granules for oral suspension

ISENTRESS is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, children, toddlers and infants from the age of 4 weeks.



- ISENTRESS 600 mg film-coated tablets

ISENTRESS 600 mg film-coated tablets is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, and paediatric patients weighing at least 40 kg.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000860
Orphan designation No
Date First Approved 20-12-2007
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Merck Sharp & Dohme Ltd.